Company Description

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.

The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.

It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Anbio Biotechnology

Country	Germany
Founded	2021
IPO Date	Feb 19, 2025
Industry	Medical Instruments & Supplies
Sector	Healthcare
Employees	27
CEO	Michael Lau

Contact Details

Address: Friedrich-Ebert-Anlage 35-37 Frankfurt am Main, 60327 Germany
Phone	49 698 7003 9170
Website	anbiobiotechnology.com

Stock Details

Ticker Symbol	NNNN
Exchange	NASDAQ
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	1982708
CUSIP Number	G0367B105
ISIN Number	KYG0367B1059
SIC Code	2835

Key Executives

Name	Position
Michael Lau M.B.A., Ph.D.	Chief Executive Officer
Suki Song CPA	Chief Financial Officer
Chris Tian	Chief Business Officer

Latest SEC Filings

Date	Type	Title
Apr 27, 2026	6-K	Report of foreign issuer
Apr 9, 2026	20-F/A	Filing
Apr 7, 2026	20-F	Annual and transition report of foreign private issuers
Feb 17, 2026	6-K	Report of foreign issuer
Jan 26, 2026	6-K	Report of foreign issuer
Dec 30, 2025	6-K	Report of foreign issuer
Nov 13, 2025	6-K	Report of foreign issuer
Apr 28, 2025	20-F	Annual and transition report of foreign private issuers
Feb 21, 2025	6-K	Report of foreign issuer
Feb 19, 2025	424B4	Prospectus

View All SEC Filings